Details for New Drug Application (NDA): 209013
✉ Email this page to a colleague
The generic ingredient in DOXAZOSIN MESYLATE is doxazosin mesylate. There are fourteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.
Summary for 209013
Tradename: | DOXAZOSIN MESYLATE |
Applicant: | Upsher Smith Labs |
Ingredient: | doxazosin mesylate |
Patents: | 0 |
Pharmacology for NDA: 209013
Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for 209013
Suppliers and Packaging for NDA: 209013
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 209013 | ANDA | Upsher-Smith laboratories, LLC | 0832-0356 | 0832-0356-11 | 100 TABLET in 1 BOTTLE (0832-0356-11) |
DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 209013 | ANDA | Upsher-Smith laboratories, LLC | 0832-0357 | 0832-0357-11 | 100 TABLET in 1 BOTTLE (0832-0357-11) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 1MG BASE | ||||
Approval Date: | Apr 17, 2018 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 2MG BASE | ||||
Approval Date: | Apr 17, 2018 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 4MG BASE | ||||
Approval Date: | Apr 17, 2018 | TE: | AB | RLD: | No |
Complete Access Available with Subscription